Haleon PLC Initiates Second Tranche of £280 Million Share Buyback Program

Haleon PLC ( (GB:HLN) ) has issued an announcement.

Haleon PLC announced the commencement of a second tranche of its share buyback program, aiming to purchase up to £280 million worth of shares. This move is part of a larger £500 million buyback initiative for 2025, with the goal of reducing the company’s share capital and fulfilling obligations under employee share plans. The buyback will be executed through an agreement with Citigroup Global Markets Limited, with trading decisions made independently of Haleon. This strategic financial maneuver is expected to impact Haleon’s market positioning by optimizing its capital structure and potentially enhancing shareholder value.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score reflects its strong financial performance and positive earnings call insights, which highlight growth in emerging markets and innovation. Mixed technical indicators suggest caution, while valuation metrics indicate moderate fair value.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 23,069,477

Technical Sentiment Signal: Hold

Current Market Cap: £32.99B

For an in-depth examination of HLN stock, go to TipRanks’ Overview page.